Sign Up to like & get recommendations! 0
Published in 2022 at "Current Opinion in Allergy and Clinical Immunology"
DOI: 10.1097/aci.0000000000000852
Abstract: Purpose of review The current review describes the incidence and risk for anaphylaxis due to allergy injections. Recent findings The incidence of fatal anaphylaxis occurs with approximately one in 7.2 million injection visits. Severe anaphylaxis… read more here.
Sign Up to like & get recommendations! 0
Published in 2022 at "Melanoma Research"
DOI: 10.1097/cmr.0000000000000815
Abstract: Immune checkpoint inhibitors (ICIs) represent a new era in stage IV melanoma treatment. These agents are generally well tolerated but have specific side effects. The granulomatous reaction is one of such ICI–related adverse events. In… read more here.
Sign Up to like & get recommendations! 1
Published in 2021 at "British Journal of Dermatology"
DOI: 10.1111/bjd.20306
Abstract: ogren syndrome (OR 0 39, 95% CI 0 22–0 71) and AIDS was associated with lower odds of mixed connective tissue disorder (OR 0 12, 95% CI 0 05–0 28). While the association between other… read more here.
Sign Up to like & get recommendations! 0
Published in 2022 at "BMJ Case Reports"
DOI: 10.1136/bcr-2022-249411
Abstract: Although novel immunotherapy has shown promise for patients with melanoma, a more activated state of the immune system may lead to adverse systemic effects. Immunotherapy-induced meningoencephalitis is a rare and seldom reported adverse effect of… read more here.
Sign Up to like & get recommendations! 2
Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-5906
Abstract: Studies have demonstrated promising outcomes of combined immune checkpoint blockade (CICB) modulating tumor cytotoxicity via targeting cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and programmed cell death 1 (PD-1). The emergence of long-term patient management has… read more here.
Sign Up to like & get recommendations! 0
Published in 2021 at "Journal of Investigative Medicine High Impact Case Reports"
DOI: 10.1177/23247096211009400
Abstract: A 40-year-old male with a right-sided neck mass was diagnosed with metastatic melanoma. A repeat positron-emission tomography after treatment with combination immunotherapy demonstrated increased hypermetabolic activity in the right supraclavicular, hilar, and mediastinal regions. Immunotherapy… read more here.
Sign Up to like & get recommendations! 0
Published in 2025 at "Journal of the Endocrine Society"
DOI: 10.1210/jendso/bvaf149.2217
Abstract: Abstract Disclosure: H. Marasandra Ramesh: None. R. Subramani: None. S. Yavuz: None. Introduction: Immune checkpoint inhibitors (ICIs) are monoclonal antibodies that enhance T-cell activation by targeting CTLA-4 and PD-1/PD-L1. Their interaction with PD-L1 on thyroid… read more here.
Sign Up to like & get recommendations! 0
Published in 2025 at "World Journal of Clinical Cases"
DOI: 10.12998/wjcc.v13.i33.113216
Abstract: The paradigm-shifting efficacy of immune checkpoint inhibitors in microsatellite instability-high colorectal cancer demands a critical appraisal of their long-term tissue effects. This editorial is a landmark case report revealing spontaneous colonic transection following pathological complete… read more here.
Sign Up to like & get recommendations! 0
Published in 2024 at "Revista espanola de enfermedades digestivas"
DOI: 10.17235/reed.2024.10550/2024
Abstract: We present the case of a 52-year-old woman diagnosed with stage IV clear cell renal cell carcinoma who received combination of surgery and systemic therapy with nivolumab (anti-PD1) and ipilimumab (anti-CTLA-4). During treatment, patient presented… read more here.
Sign Up to like & get recommendations! 0
Published in 2024 at "Frontiers in Aging Neuroscience"
DOI: 10.3389/fnagi.2024.1412006
Abstract: The targeting of amyloid-beta (Aβ) plaques therapeutically as one of the primary causes of Alzheimer’s disease (AD) dementia has been an ongoing effort spanning decades. While some antibodies are extremely promising and have been moved… read more here.
Sign Up to like & get recommendations! 0
Published in 2024 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2024.1330271
Abstract: Introduction Immune checkpoint inhibitors are the mainstay of treatment in patients with unresectable or metastatic melanoma. Combination immunotherapy with ipilimumab and nivolumab has shown to improve survival outcomes as compared to single agent immunotherapy in… read more here.